Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2022; 21(03): 192-199
DOI: 10.1055/s-0042-1751031
Original Article

Incidental Findings on 18F-Fluorocholine PET/CT for Parathyroid Imaging

Wouter A.M. Broos
1   Department of Nuclear Medicine, Northwest Clinics, Alkmaar, the Netherlands
2   CAPHRI School for Care and Public Health Research, Maastricht University, Maastricht, the Netherlands
,
Remco J.J. Knol
1   Department of Nuclear Medicine, Northwest Clinics, Alkmaar, the Netherlands
,
Friso M. van der Zant
1   Department of Nuclear Medicine, Northwest Clinics, Alkmaar, the Netherlands
,
Nicolaas C. Schaper
2   CAPHRI School for Care and Public Health Research, Maastricht University, Maastricht, the Netherlands
3   Division of Endocrinology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands
,
Maurits Wondergem
1   Department of Nuclear Medicine, Northwest Clinics, Alkmaar, the Netherlands
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction 18F-choline positron emission tomography/computed tomography (PET/CT) is an upcoming imaging technique for the localization of hyperfunctioning parathyroid glands. However, 18F-choline is a nonspecific tracer that also accumulates in malignancies, inflammatory lesions, and several other benign abnormalities. The aim of this study was to determine the occurrence and relevance of incidental findings on 18F-choline PET/CT for parathyroid localization.

Materials and Methods 18F-choline PET/CTs performed in our center for parathyroid localization from 2015 to 2019 were reviewed. Abnormal uptake of 18F-choline, with or without anatomical substrate on the co-registered low-dose CT and also incidental findings on CT without increased 18F-choline uptake were recorded. Each finding was correlated with follow-up data from the electronic medical records.

Results A total of 388 18F-choline PET/CTs were reviewed, with 247 incidental findings detected in 226 patients (58%): 82 18F-choline positive findings with corresponding pathology on CT, 16 without CT substrate, and 149 18F-choline negative abnormalities on CT. Malignant lesions were detected in 10/388 patients (2.6%). Of all 98 detected 18F-choline positive lesions, 15 were malignant (15.3%), concerning 4 metastases and 11 primary malignancies: breast carcinoma (n = 7), lung carcinoma (n = 2), thyroid carcinoma (n = 1), and skin melanoma (n = 1).

Conclusion Clinically relevant incidental findings were observed in a substantial number of patients. In 15.3% of the incidental 18F-choline positive findings, the lesions were malignant. These data contribute to better knowledge of 18F-choline distribution, enhance interpretation of 18F-choline PET/CT, and guide follow-up of incidental findings. Attention should especially be paid to breast lesions in this particular patient group with hyperparathyroidism in which women are typically over-represented.

Keywords

18F-fluorocholine - PET/CT - hyperparathyroidism - incidental findings

Informed Consent

All patients gave written informed consent for the use of their anonymized data for scientific purposes. Besides the standard imaging protocol and clinical management, no additional measurements or actions affecting the patient were performed. The study was approved by the institutional research department and performed in accordance with the Declaration of Helsinki. Approval of the local ethical committee for the present study was not necessary since the study does not fall within the scope of the Dutch Medical Research Involving Human Subjects Act (section 1.b WMO, 26th February 1998).




Publication History

Article published online:
16 August 2022

© 2022. World Association of Radiopharmaceutical and Molecular Therapy (WARMTH). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Thanseer N, Bhadada SK, Sood A. et al. Comparative effectiveness of ultrasonography, 99mTc-Sestamibi, and 18F-Fluorocholine PET/CT in detecting parathyroid adenomas in patients with primary hyperparathyroidism. Clin Nucl Med 2017; 42 (12) e491-e497
    CrossrefPubMedSearch in Google Scholar
  • 2 Cuderman A, Senica K, Rep S. et al. 18F-Fluorocholine PET/CT in primary hyperparathyroidism: superior diagnostic performance to conventional scintigraphic imaging for localization of hyperfunctioning parathyroid glands. J Nucl Med 2020; 61 (04) 577-583
    CrossrefPubMedSearch in Google Scholar
  • 3 Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 2007; 37 (06) 400-419
    CrossrefPubMedSearch in Google Scholar
  • 4 Treglia G, Giovannini E, Di Franco D. et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med 2012; 26 (06) 451-461
    CrossrefPubMedSearch in Google Scholar
  • 5 Quak E, Lheureux S, Reznik Y, Bardet S, Aide N. F18-choline, a novel PET tracer for parathyroid adenoma?. J Clin Endocrinol Metab 2013; 98 (08) 3111-3112
    CrossrefPubMedSearch in Google Scholar
  • 6 Beheshti M, Haroon A, Bomanji JB, Langsteger W. Fluorocholine PET/computed tomography: physiologic uptake, benign findings, and pitfalls. PET Clin 2014; 9 (03) 299-306
    CrossrefPubMedSearch in Google Scholar
  • 7 Calabria F, Chiaravalloti A, Cicciò C. et al. PET/CT with 18F-choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18F-choline PET/CT bio-distribution and pitfalls. A southern Italian experience. Nucl Med Biol 2017; 51: 40-54
    CrossrefPubMedSearch in Google Scholar
  • 8 Broos WAM, Wondergem M, van der Zant FM, Knol RJJ. Tertiary hyperparathyroidism with renal osteodystrophy on 18F-fluorocholine PET/CT. Clin Nucl Med 2018; 43 (10) 766-768
    CrossrefPubMedSearch in Google Scholar
  • 9 Burgers AMG, Wondergem M, van der Zant FM, Knol RJJ. Incidental detection of a melanoma by 18F-fluorocholine PET/CT performed for evaluation of primary hyperparathyroidism. Clin Nucl Med 2018; 43 (04) 265-266
    CrossrefPubMedSearch in Google Scholar
  • 10 García JR, Ponce A, Canales M, Ayuso J, Moragas M, Soler M. [Detection of second tumors in 11C-choline PET/CT studies performed due to biochemical recurrence of prostate cancer]. Rev Esp Med Nucl Imagen Mol 2014; 33 (01) 28-31
    PubMedSearch in Google Scholar
  • 11 Sollini M, Pasqualetti F, Perri M. et al. Detection of a second malignancy in prostate cancer patients by using [(18)F]Choline PET/CT: a case series. Cancer Imaging 2016; 16 (01) 27
    CrossrefPubMedSearch in Google Scholar
  • 12 Welle CL, Cullen EL, Peller PJ. et al. 11C-Choline PET/CT in recurrent prostate cancer and nonprostatic neoplastic processes. Radiographics 2016; 36 (01) 279-292
    CrossrefPubMedSearch in Google Scholar
  • 13 How Kit N, Dugué AE, Sevin E. et al. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy. Nucl Med Commun 2016; 37 (04) 348-355
    CrossrefPubMedSearch in Google Scholar
  • 14 Albano D, Durmo R, Bertagna F, Giubbini R. 18F-choline PET/CT incidental thyroid uptake in patients studied for prostate cancer. Endocrine 2019; 63 (03) 531-536
    CrossrefPubMedSearch in Google Scholar
  • 15 Yeh MW, Ituarte PH, Zhou HC. et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013; 98 (03) 1122-1129
    Search in Google Scholar
  • 16 Ahmad Saad FF, Zakaria MH, Appanna B. PET/CT analysis of 21 patients with breast cancer: physiological distribution of 18F-choline and diagnostic pitfalls. J Int Med Res 2018; 46 (08) 3138-3148
    CrossrefPubMedSearch in Google Scholar
  • 17 Michaud L, Burgess A, Huchet V. et al. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism?. J Clin Endocrinol Metab 2014; 99 (12) 4531-4536
    CrossrefPubMedSearch in Google Scholar
  • 18 Michaud L, Balogova S, Burgess A. et al. A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine (Baltimore) 2015; 94 (41) e1701
    CrossrefPubMedSearch in Google Scholar
  • 19 Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 2006; 15 (11) 2020-2026
    CrossrefPubMedSearch in Google Scholar
  • 20 Parvinian A, Martin-Macintosh EL, Goenka AH. et al. 11C-Choline PET/CT for detection and localization of parathyroid adenomas. AJR Am J Roentgenol 2018; 210 (02) 418-422
    CrossrefPubMedSearch in Google Scholar
  • 21 Wyss MT, Weber B, Honer M. et al. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging 2004; 31 (03) 312-316
    CrossrefPubMedSearch in Google Scholar
  • 22 Snider SA, Margison KD, Ghorbani P. et al. Choline transport links macrophage phospholipid metabolism and inflammation. J Biol Chem 2018; 293 (29) 11600-11611
    CrossrefPubMedSearch in Google Scholar
  • 23 Masselli G, Monti R, Guida M, Gualdi G. Giant Schmorl's node may cause high uptake and mimic a bone metastasis on 18F-choline positron emission tomography/computed tomography. World J Nucl Med 2015; 14 (02) 140-141
    Thieme ConnectPubMedSearch in Google Scholar
  • 24 Gu CN, Hunt CH, Lehman VT. et al. Benign fibrous dysplasia on [(11)C]choline PET: a potential mimicker of disease in patients with biochemical recurrence of prostate cancer. Ann Nucl Med 2012; 26 (07) 599-602
    CrossrefPubMedSearch in Google Scholar
  • 25 Wondergem M, van der Zant FM, van der Ploeg T, Knol RJ. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nucl Med Commun 2013; 34 (10) 935-945
    CrossrefPubMedSearch in Google Scholar
  • 26 Florimonte L, Orunesu E, Castellani M, Longari V, Cortelezzi A. 18F-Choline PET/CT-positive lytic bone lesions in prostate cancer and accidental myeloma detection. Clin Nucl Med 2016; 41 (05) 394-396
    CrossrefPubMedSearch in Google Scholar
  • 27 Sheldon JA, Yap KK, Taubman KL, Schlicht SM. Prevalence of non 18 F-fluorodeoxyglucose-avid incidental findings of clinical significance on whole body positron emission tomography/computed tomography: a review of 500 consecutive cases. J Med Imaging Radiat Oncol 2018; 62 (02) 194-202
    CrossrefPubMedSearch in Google Scholar
  • 28 Guo HH, Moradi F, Iagaru A. Clinical significance of extraskeletal computed tomography findings on 18F-NaF PET/CT performed for osseous metastatic disease evaluation. Nucl Med Commun 2016; 37 (09) 975-982
    CrossrefPubMedSearch in Google Scholar
  • 29 Kan H, van der Zant FM, Wondergem M, Knol RJJ. Incidental extra-cardiac findings on 13N-ammonia myocardial perfusion PET/CT. J Nucl Cardiol 2017; 24 (06) 1860-1868
    CrossrefPubMedSearch in Google Scholar
  • 30 MacMahon H, Naidich DP, Goo JM. et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology 2017; 284 (01) 228-243
    Search in Google Scholar
  • 31 Berland LL, Silverman SG, Gore RM. et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 2010; 7 (10) 754-773
    CrossrefPubMedSearch in Google Scholar